Table 1.
Characteristics of included studies.
| References | Nation | SNPs | Case | Control | Types of case and control | Study design | Genotype method | Nos. |
|---|---|---|---|---|---|---|---|---|
| Zhao et al. (2020) | China | IFN-γ: rs2430561(874T/A) | 233 (185/48) | 200 (147/53) | Patients (P/H/V*:189/23/21) vs. healthy individuals | Case–control study | SNaPshot system | 7 |
| Perez-Is et al. (2019) | Spain | CTSG: rs45567233 | 329 (245/84) | 415 (295/120) | Patients (P/H/V:196/56/77) vs. healthy individuals | Case–control study | PCR-RFLP | 7 |
| Hou et al. (2018) | China | TNF-α: rs1799964, rs1800630, rs1799724, rs1800750,rs1800629, rs361525 | 233 (185/48) | 200 (147/53) | Patients (P/H/V:189/23/21) vs. healthy individuals | Case–control study | SNaPshot system | 7 |
| Jiang et al. (2016) | China | VDR: rs731236, rs1544410, rs2228570, rs7975232 | 233 (185/48) | 200(147/53) | Patients (P/H/V:189/23/21) vs. healthy individuals | Case–control study | SNaPshot system | 7 |
| Valle-Garay et al. (2013) | Spain | tPA: rs4646972, rs1799889 | 261 (186/75) | 299 (205/94) | Patients (P/H: 224 /37) vs. healthy individuals | Case–control study | PCR-RFLP | 8 |
| Montes et al. (2006) | Spain | TLR2: Arg753Gln TLR4: rs498670, rs498671 | 80 (54/26) | 155 | Patients (P/H:67/13) vs. healthy individuals | Case–control study | PCR-RFLP | 8 |
| Asensi et al. (2003) | Spain | IL-1α: rs1800587 IL-1β: rs1143634 TNF-α: rs 1800629 IL-6: rs1800795 | 52 | 109 | Patients (P/H:43/9) vs. healthy individuals | Case–control study | PCR-RFLP | 8 |
| Wang et al. (2017) | China | COX-2: rs20417, rs689466 | 189 (156/33) | 220 (167/53) | Patients (P:189) vs. healthy individuals | Case–control study | SNaPshot system | 7 |
| Jiang et al. (2020) | China | IL-1α: rs17561, rs1800587 IL-1β: rs16944, rs1143627, rs1143634, rs2853550 IL1RN: rs4251961, rs419598, rs315951 IL-4: rs2243248, rs2243250 IL-6: rs1800795, rs1800796, rs1800797 IL-8: rs4073, rs2227306, rs2227307 IL-10: rs3024491, rs3024496, rs1800871, rs1800872, rs1800896 IL17A: rs2275913 IF17F: rs763780 | 233 (185/48) | 200 (147/53) | Patients (P:189) vs. healthy individuals | Case–control study | SNaPshot system | 7 |
| Osman et al. (2016) | Saudi Arabia | IL-1β: rs16944, rs1143634 IL-1α: rs1800587 TLR2: rs3804099 TLR4: rs4986790, rs4986791 IL-1R: rs2234650 TNF-α: rs1800629, rs361525 IL1RN: rs315952 | 52 (22/30) | 103 (44/59) | Hematogenous osteomyelitis patients vs. healthy individuals | Case–control study | PCR | 6 |
| Osman et al. (2015) | Saudi Arabia | IL-4: rs2070874, rs2243248 IL-10: rs1800896, rs1800871, rs1800872 TGF-B1: rs1800470 IL-4R: rs1801275 IL-12B: rs3212227 IL-2: rs2069762 | 52 (22/30) | 103 (44/59) | Hematogenous osteomyelitis patients vs. healthy individuals | Case–control study | PCR | 6 |
| Kong et al. (2017) | China | MMP1: rs1799750, rs1144393 | 80 (41/40) | 81 (37/44) | Osteomyelitis patients vs. healthy individuals | Case–control study | PCR-RFLP | 6 |
| Ocana et al. (2007) | Spain | BAX: G(-248)A | 80 (53/27) | 220 | Osteomyelitis patients vs. healthy individuals | Case–control study | PCR-RFLP | 8 |
| Tsezou et al. (2008) | Greek | IL-1α: rs1800587 IL-4: rs2243248, rs2243250 IL-6: rs1800795 | 81 (42/39) | 110 (62/48) | Osteomyelitis patients vs. healthy individuals | Case–control study | PCR-SSP assay | 6 |
*
P/H/V represents the number of patients with posttraumatic osteomyelitis, or hematogenous osteomyelitis, or vascular insufficiency-related osteomyelitis.